Abbott Laboratories 2012 Q1 Form 10-Q Summary
Business context and reporting period
Abbott Laboratories filed an unaudited Form 10-Q for the three months ended March 31, 2012. Abbott operates globally across proprietary and established pharmaceuticals, nutritionals, diagnostics, vascular products, diabetes care and medical optics. The company planned to separate its proprietary pharmaceuticals business into a new public company, AbbVie, through a tax-free distribution expected by the end of 2012.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $9.457 billion | $9.041 billion | +4.6% |
| Operating earnings | $1.576 billion | $1.301 billion | +21.1% |
| Net earnings | $1.242 billion | $864 million | +43.8% |
| Diluted EPS | $0.78 | $0.55 | +41.8% |
| Gross margin | 60.6% | 57.3% | +330 basis points |
| Operating margin | 16.7% | 14.4% | +230 basis points |
| Net margin | 13.1% | 9.6% | +350 basis points |
| Operating cash flow | $2.225 billion | $2.011 billion | +10.6% |
Cash and cash equivalents were $4.346 billion at March 31, 2012, compared with $6.813 billion at December 31, 2011. Current investments increased to $5.181 billion from $1.285 billion. Total debt, including short-term borrowings and current and long-term debt, was approximately $16.647 billion. Abbott reported $6.7 billion of unused credit facilities supporting commercial paper borrowings.
Capital expenditures were $453 million, acquisitions of businesses and technology were $671 million, purchases of investment securities were $3.900 billion, share repurchases were $988 million, and dividends paid were $759 million. Cash decreased by $2.467 billion during the quarter, ending at $4.346 billion.
Material changes versus the prior comparable period
- Sales increased 4.6%, reflecting unit growth partly offset by unfavorable foreign exchange. Excluding currency effects, sales increased 5.9%.
- Proprietary Pharmaceutical Products sales rose 7.1%, led by HUMIRA; Nutritional Products increased 10.1%; Diagnostic Products increased 6.1%; Established Pharmaceutical Products declined 1.6%; and Vascular Products declined 4.9%.
- HUMIRA sales increased 23% in the United States and 14% internationally. Vascular sales were affected by the wind-down of certain royalty and supply agreements, including Promus.
- Gross margin improved primarily because of favorable product mix and improved margins across all reportable segments.
- Research and development expense increased 8.1%, while selling, general and administrative expense increased 5.3%.
- Net earnings benefited from approximately $60 million of income from the resolution of a contractual agreement and from the absence of the $137 million accounting-change charge recorded in the first quarter of 2011.
Guidance, outlook, commentary, risks and unusual items
- Management stated that annual operating cash flow is expected to continue to exceed capital expenditures and cash dividends. The filing does not provide a specific earnings or revenue forecast.
- Abbott recorded $150 million of acquired in-process and collaboration research and development expense for a global JAK1 inhibitor collaboration. Up to approximately $1.2 billion of additional milestone payments may become payable.
- A $400 million payment related to a collaboration entered into in the fourth quarter of 2011 and a $134 million Solvay sales-milestone payment were made during the quarter. An additional $50 million clinical-development milestone charge was recorded.
- Abbott recorded an additional $100 million charge in the first quarter for the Depakote investigation, following a $1.5 billion charge in the third quarter of 2011. In May 2012, Abbott agreed to approximately $1.6 billion of federal, state Medicaid and consumer-protection payments, plus a corporate integrity agreement and probation; court approval was pending. Payment was expected to be material to 2012 cash flows.
- Legal and environmental reserves were approximately $1.72 billion at March 31, 2012, with an estimated possible-loss range of approximately $1.71 billion to $1.74 billion.
- Abbott identified ongoing investigations involving certain medical-device sales and marketing practices and patent litigation involving products including Niaspan, Norvir and vascular stents.
- Health-care reform continues to increase Medicaid rebates and other pharmaceutical costs. A 2.3% U.S. medical-device excise tax was scheduled to begin in 2013.
- Restructuring programs remained in progress, with additional charges expected during 2012 for diagnostic product transfers and regulatory re-registration timelines.
- Abbott implemented a new enterprise resource planning system for a large portion of its U.S. operations. Management concluded that disclosure controls were effective and stated that no material adverse change in internal control had occurred.
Most important facts for investors to verify
- Timing, tax treatment and final execution of the planned AbbVie separation.
- Cash impact and final approval of the Depakote settlement, including the corporate integrity agreement and probation terms.
- Progress, costs and potential milestone obligations under the JAK1 and other collaboration agreements.
- Sustainability of HUMIRA-driven pharmaceutical growth and the effects of pricing pressure, generic competition and foreign exchange.
- Whether operating cash flow continues to cover capital expenditures, dividends, litigation payments and share repurchases.
- Debt maturities, commercial-paper refinancing capacity and the effect of interest-rate and foreign-exchange exposures.
- Remaining restructuring charges and the impact of health-care reform, Medicaid rebates and the 2013 medical-device excise tax.